期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 115, 期 5, 页码 1258-1266出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200524356
关键词
-
资金
- NICHD NIH HHS [P30 HD018655, P30 HD18655] Funding Source: Medline
- NIDDK NIH HHS [R01 DK053813-10, P30 DK049216, K01 DK02804, R01 DK53813, P30 DK49216, R01 DK053813] Funding Source: Medline
Solute carrier family 11, member 2 (SLC11A2) is the only transmembrane iron transporter known to be involved in cellular iron uptake. it is widely expressed and has been postulated to play important roles in intestinal iron absorption, erythroid iron utilization, hepatic iron accumulation, placental iron transfer, and other processes. Previous studies have suggested that other transporters might exist, but their physiological significance remained uncertain. To define the activities of Slc11a2 in vivo, we inactivated the murine gene that encodes it globally and selectively. We found that fetal Slc11a2 is not needed for materno-fetal iron transfer but that Slc11a2 activity is essential for intestinal non-heme iron absorption after birth. Slc11a2 is also required for normal hemoglobin production during the development of erythroid precursors. However, hepatocytes and most other cells must have an alternative, as-yet-unknown, iron uptake mechanism. We previously showed that Slc11a2 serves as the primary portal for intestinal iron entry in hemochromatosis. However, inactivation of murine Hfe ameliorates the phenotype of animals lacking Slc11a2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据